Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has received a consensus rating of "Moderate Buy" from the fourteen research firms that are presently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $30.56.

A number of research firms have recently commented on KROS. Bank of America downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Scotiabank decreased their price objective on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. Truist Financial dropped their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Wedbush restated a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. Finally, HC Wainwright lowered their price target on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, May 8th.

Insider Activity

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider owned 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 22.90% of the company's stock.

Institutional Trading of Keros Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its stake in Keros Therapeutics by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company's stock valued at $1,549,000 after acquiring an additional 2,462 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Keros Therapeutics by 7.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 279,682 shares of the company's stock worth $4,427,000 after purchasing an additional 19,562 shares during the last quarter. AlphaQuest LLC grew its stake in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after purchasing an additional 2,964 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Keros Therapeutics in the fourth quarter worth about $461,000. Finally, Swiss National Bank increased its holdings in Keros Therapeutics by 4.8% in the fourth quarter. Swiss National Bank now owns 59,000 shares of the company's stock valued at $934,000 after buying an additional 2,700 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Price Performance

NASDAQ:KROS traded down $0.05 during mid-day trading on Friday, reaching $13.40. The company's stock had a trading volume of 517,755 shares, compared to its average volume of 863,690. The stock has a market cap of $544.31 million, a P/E ratio of -74.44 and a beta of 1.26. The company's fifty day simple moving average is $14.00 and its two-hundred day simple moving average is $12.82. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $3.63. The company had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a net margin of 1.96% and a return on equity of 0.75%. During the same period in the previous year, the company earned ($1.21) EPS. Sell-side analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.